RSV Vaccine Market Size, Share, Growth, and Industry Analysis, By Type (Clinical I,Clinical II,Clinical III,Preclinical,Being Developed), By Application (Elderly Vaccine,Infant Vaccine,Others), Regional Insights and Forecast to 2035

RSV Vaccine Market Overview

The global RSV Vaccine Market size is projected to grow from USD 214.74 million in 2026 to USD 230.42 million in 2027, reaching USD 404.86 million by 2035, expanding at a CAGR of 7.3% during the forecast period.

The RSV Vaccine Market Report reflects a transformation following multiple regulatory authorizations: 3 adult RSV vaccines were authorized for older adults between 2023–2024, and 30+ vaccine candidates were in clinical development as of early 2025. Global disease burden estimates report 3.6 million hospitalizations and roughly 100,000 deaths annually among children under 5 years, driving demand for maternal and infant prevention strategies. Pediatric clinical trial activity included 26 U.S. investigational new drug (IND) pediatric entries and 15 live-attenuated pediatric candidates in 2024, underscoring pipeline depth; the RSV Vaccine Market Analysis shows accelerated R&D investment and prioritized B2B manufacturing partnerships in 2023–2025.

The USA RSV Vaccine Market Analysis highlights regulatory milestones and uptake: 3 RSV vaccines were recommended for adults by U.S. advisory bodies by 2024–2025, and CDC guidance recommends vaccination for all adults aged 75+ and adults 50–74 at increased risk. Annual U.S. RSV hospitalization estimates show tens of thousands of hospitalizations in older adults and between 58,000–80,000 annual hospitalizations among children under 5 in pre-vaccine seasons. Clinical trial enrollment for adult vaccine pivotal studies included >35,000 participants in one major Phase III program, and maternal immunization trials tracked infant outcomes for 90 and 180 days post-birth in thousands of dyads, shaping the RSV Vaccine Market Forecast for domestic rollout.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: The RSV Vaccine Market is driven by the approval of three adult vaccines and the ongoing development of over 30 vaccine candidates globally.
• Major Market Restraint: Clinical delays affected 26 pediatric vaccine programs due to regulatory holds issued in late 2024, extending development timelines by 12 to 18 months.
• Emerging Trends: More than 200 new vaccine formulations and 15 live-attenuated RSV candidates are being tested across global clinical pipelines.
• Regional Leadership: North America leads with three approved vaccines, while Asia-Pacific has over 500 active clinical trial sites—the highest number among all regions.
• Competitive Landscape: The RSV Vaccine Industry is dominated by seven major companies, with Pfizer and GSK holding the strongest positions across global adult and maternal vaccine markets.
• Market Segmentation: The RSV Vaccine Market includes five key stages of development—Clinical I, Clinical II, Clinical III, Preclinical, and Being Developed—with four ongoing Phase III programs.
• Recent Development: Between 2023 and 2025, over 20 new manufacturing collaborations were announced, and the first mRNA-based RSV vaccine achieved regulatory approval worldwide.

RSV Vaccine Market Latest Trends

The RSV Vaccine Market Trends indicate rapid adoption in adult immunization with 3 vaccines authorized for adults in 2023–2024, and expanded regulatory activity in 2024–2025 targeting older adults and pregnant people. Maternal immunization trials report infant protection efficacy near 82% in the first 90 days and about 70% through 180 days in published trial cohorts, driving RSV Vaccine Market Insight into maternal programs. Adult pivotal trials enrolled cohorts of >35,000 participants in one Phase III program, and vaccine efficacy readouts ranged from 68% to 84% against RSV-LRTD in different endpoints. Pipeline depth remains high: 30+ candidates were in clinical development in early 2025, with 4+ Phase III programs ongoing and 26 pediatric INDs recorded in 2024. Distribution channels show public health and commercial mixes: seasonal adult campaigns and prenatal programs target millions of doses per season in high-income markets. Technology trends include mRNA, recombinant protein, and live-attenuated platforms, with mRNA approvals marking the first mRNA RSV vaccine licensed for adults in 2024, shifting the competitive structure in the RSV Vaccine Market Report and RSV Vaccine Industry Analysis for B2B players.

RSV Vaccine Market Dynamics

DRIVER

"Rapid regulatory approvals and high disease burden drive adoption."

The RSV Vaccine Market Driver centers on regulatory breakthroughs and measurable disease burden: 3 adult vaccines were authorized between 2023–2024, and global pediatric burden estimates show 3.6 million hospitalizations and roughly 100,000 deaths annually among children under 5, with 97% of pediatric deaths occurring in low- and middle-income countries. Large adult trials enrolled tens of thousands, for example >35,000 participants in a Phase III adult study, producing efficacy signals of 68%–84% against RSV lower respiratory tract disease endpoints. These data accelerated national immunization program planning in 2024–2025 and created demand for scaled manufacturing capacity where B2B providers increased fill-finish capacity by double-digit percentages in several markets.

RESTRAINT

"Pediatric trial holds, safety signals, and supply complexities restrict rapid pediatric rollout."

Clinical holds and safety concerns created restraints: in December 2024, pediatric RSV vaccine trials were placed on hold in multiple programs, affecting an estimated 26 pediatric INDs and 15 live-attenuated candidates, delaying pediatric development timelines by 12–18 months in many cases. Regulatory caution followed rare adverse event signals in small subgroups from an early infant trial that implicated enhanced respiratory disease concerns, prompting investigational holds and additional safety studies. This constrained the RSV Vaccine Market Growth for the infant segment and increased risk premiums for investors and manufacturers.

OPPORTUNITY

"Maternal immunization, mRNA platform scalability, and LMIC access initiatives."

Opportunities in the RSV Vaccine Market include maternal immunization, where trials demonstrated infant protection of ~82% in the first 90 days and close to 70% through 180 days post-birth in key datasets, prompting global policy consideration for prenatal vaccination campaigns covering millions of pregnancies per year in high-burden settings. mRNA platform approvals provide scale and flexible manufacturing: the first mRNA RSV vaccine moved to market in 2024, and mRNA process technology can reduce development timelines by 30–50% compared to traditional protein subunit platforms.

CHALLENGE

"Pricing, procurement complexity, and differentiated product claims hinder uniform uptake."

The RSV Vaccine Market Challenge centers on varied national procurement pathways and differentiated claims: adult vaccines have received approvals on differing age bands and indications (e.g., elderly adults 60+, pregnant people at 32–36 weeks in maternal trials), which created heterogeneity in national immunization program eligibility and procurement cycles. Negotiated tender sizes vary widely: initial procurement commitments ranged from tens of thousands of doses at the country level to millions at the federal level in large markets, complicating supply forecasting.

RSV Vaccine Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

The RSV Vaccine Market Segmentation by type and application is a central B2B planning tool: by type the landscape includes Clinical I, Clinical II, Clinical III, Preclinical, and Being Developed categories with 30+ clinical candidates and 26 pediatric INDs noted in 2024; by application the industry separates Elderly Vaccine, Infant Vaccine, and Others such as maternal immunization and immunocompromised populations.

BY TYPE

Clinical I: Clinical I stage RSV vaccine activity included dozens of first-in-human trials: in 2024 there were roughly 10–20 active Phase I trials testing safety and immunogenicity for live-attenuated, recombinant protein, and mRNA constructs. Typical Phase I cohorts ranged from 20 to 200 healthy adult volunteers per study, with many trials enrolling 48–200 participants to assess safety signals and dose selection.

The Clinical I segment of the RSV Vaccine Market is estimated at USD 28.42 million in 2025, accounting for a 14.2% share, and expected to grow at a CAGR of 7.0% through 2034.

Top 5 Major Dominant Countries in the Clinical I Segment

• United States: Valued at USD 7.9 million with a 27.8% share and 7.1% CAGR, driven by early-stage clinical research programs and federal vaccine development support.
• Germany: Estimated at USD 4.3 million with a 15.1% share and 7.0% CAGR, due to increased funding for infectious disease vaccine trials.
• China: Projected at USD 3.8 million with a 13.4% share and 7.3% CAGR, supported by expansion in clinical testing facilities.
• Japan: Holds USD 3.1 million with an 11.0% share and 6.9% CAGR, attributed to advancements in recombinant vaccine technologies.
• United Kingdom: At USD 2.7 million with a 9.5% share and 7.1% CAGR, driven by university-led collaborative research initiatives.

Clinical II: Clinical II activity encompassed mid-stage trials, with typical trial sizes of 200–1,000 participants per protocol in 2023–2024, and about 10–20 active Phase II RSV vaccine trials globally. These studies evaluated immunogenicity across target age groups (e.g., adults >60 years, pregnant people in 32–36 weeks gestation) and tested dose regimens such as single versus two-dose schedules.

The Clinical II segment is valued at USD 39.83 million in 2025, holding a 19.9% share, and anticipated to expand at a CAGR of 7.2% through 2034.

Top 5 Major Dominant Countries in the Clinical II Segment

• United States: Estimated at USD 11.5 million with a 28.8% share and 7.2% CAGR, supported by mid-phase vaccine trials and regulatory funding.
• China: Valued at USD 8.4 million with a 21.1% share and 7.4% CAGR, driven by clinical expansion under national health programs.
• Germany: Projected at USD 6.5 million with a 16.3% share and 7.1% CAGR, due to government-backed RSV research projects.
• Japan: At USD 5.7 million with a 14.3% share and 7.0% CAGR, led by improved biotechnological capabilities.
• France: Estimated at USD 4.8 million with a 12.0% share and 7.1% CAGR, encouraged by increased vaccine development partnerships.

Clinical III: Clinical III trials represented the pivotal evidence base: 4+ Phase III adult trials were active or completed by 2024, several enrolling >25,000 participants combined to demonstrate efficacy against RSV-LRTD endpoints; for example, one large Phase III adult program included more than 35,000 adults aged ≥60 years.

The Clinical III segment is projected at USD 63.24 million in 2025, representing the largest share of 31.6%, with a CAGR of 7.5% through 2034.

Top 5 Major Dominant Countries in the Clinical III Segment

• United States: Valued at USD 19.7 million with a 31.1% share and 7.4% CAGR, supported by advanced late-stage vaccine trials and FDA acceleration programs.
• China: Estimated at USD 14.6 million with a 23.1% share and 7.7% CAGR, driven by major pharmaceutical collaborations.
• Germany: Holds USD 10.2 million with a 16.1% share and 7.4% CAGR, attributed to ongoing vaccine candidate evaluations.
• United Kingdom: At USD 9.1 million with a 14.4% share and 7.3% CAGR, driven by robust clinical infrastructure.
• Japan: Valued at USD 8.0 million with a 12.7% share and 7.2% CAGR, due to strategic vaccine pipeline diversification.

Preclinical: Preclinical activity in 2024–2025 included dozens of candidate programs—estimates indicate >20 preclinical RSV vaccine projects testing novel antigen designs, adjuvant systems, and delivery approaches such as intranasal live-attenuated candidates.

The Preclinical segment of the RSV Vaccine Market is valued at USD 34.02 million in 2025, contributing a 17.0% share, and is expected to record a CAGR of 7.1% through 2034.

Top 5 Major Dominant Countries in the Preclinical Segment

• United States: Estimated at USD 10.3 million with a 30.3% share and 7.2% CAGR, fueled by government-backed animal model studies.
• Germany: Valued at USD 6.9 million with a 20.3% share and 7.0% CAGR, led by increased investment in immunology research.
• China: Projected at USD 6.0 million with a 17.6% share and 7.3% CAGR, due to preclinical innovation in nanoparticle-based vaccines.
• Japan: At USD 5.3 million with a 15.6% share and 7.1% CAGR, driven by cross-sector vaccine R&D collaborations.
• India: Holds USD 4.5 million with a 13.2% share and 7.4% CAGR, supported by expanding biopharma research facilities.

Being Developed: The “Being Developed” category captures late discovery and early translational programs: in 2024, approximately 10–15 candidates were in translational stages with plans to enter clinical trials within 12–24 months. These programs included next-generation scaffolds, cross-protective antigen constructs, and combination maternal/infant strategies.

The Being Developed segment is estimated at USD 34.62 million in 2025, accounting for a 17.3% share, and is projected to grow at a CAGR of 7.4% through 2034.

Top 5 Major Dominant Countries in the Being Developed Segment

• United States: Valued at USD 10.8 million with a 31.2% share and 7.3% CAGR, due to multiple candidates under regulatory evaluation.
• China: Estimated at USD 8.9 million with a 25.7% share and 7.5% CAGR, supported by rapid biotech commercialization.
• Germany: Holds USD 6.1 million with a 17.6% share and 7.2% CAGR, driven by European vaccine consortium projects.
• France: Projected at USD 4.9 million with a 14.2% share and 7.3% CAGR, owing to expanding immunization R&D.
• Japan: Valued at USD 3.9 million with an 11.3% share and 7.2% CAGR, backed by government vaccination programs.

BY APPLICATION

Elderly Vaccine: Elderly vaccine applications represent one of the earliest commercial markets: adults aged ≥60 or ≥75 constitute tens of millions of eligible people in high-income countries, and clinical programs enrolled large elderly cohorts—one Phase III adult study enrolled >35,000 participants aged ≥60. Public health recommendations in 2024–2025 targeted adults 75+ universally and adults 50–74 with risk factors, focusing initial rollout on these cohorts.

The Elderly Vaccine segment accounts for USD 89.06 million in 2025, representing the largest share of 44.5%, and is growing at a CAGR of 7.4%.

Top 5 Major Dominant Countries in the Elderly Vaccine Application

• United States: Estimated at USD 26.8 million with a 30.1% share and 7.3% CAGR, due to aging population and strong immunization demand.
• Japan: Valued at USD 18.5 million with a 20.8% share and 7.2% CAGR, supported by geriatric healthcare programs.
• Germany: Holds USD 15.9 million with a 17.9% share and 7.4% CAGR, driven by government-backed vaccination awareness.
• China: At USD 14.6 million with a 16.4% share and 7.5% CAGR, led by healthcare infrastructure expansion.
• France: Projected at USD 13.3 million with a 14.8% share and 7.3% CAGR, attributed to preventive healthcare initiatives.

Infant Vaccine: Infant vaccine demand is primarily addressed by maternal immunization and direct infant vaccines; maternal immunization trials included thousands of pregnant participants and measured infant protection for 90 and 180 day endpoints, with infant protection efficacy estimates near 82% at 90 days in key trials.

The Infant Vaccine segment is valued at USD 70.05 million in 2025, accounting for a 35.0% share, and is expected to register a CAGR of 7.2% through 2034.

Top 5 Major Dominant Countries in the Infant Vaccine Application

• United States: Estimated at USD 20.3 million with a 29.0% share and 7.3% CAGR, driven by pediatric immunization programs.
• China: Valued at USD 17.1 million with a 24.4% share and 7.4% CAGR, supported by expanding childhood vaccination coverage.
• India: Holds USD 11.8 million with a 16.8% share and 7.5% CAGR, driven by increased vaccine affordability.
• Japan: At USD 10.9 million with a 15.6% share and 7.1% CAGR, due to early-stage RSV prevention programs.
• Germany: Projected at USD 9.9 million with a 14.2% share and 7.2% CAGR, influenced by strong infant healthcare policies.

Others: The “Others” application bucket includes immunocompromised patients, transplant recipients, and niche occupational groups; these populations combined represent smaller but clinically important cohorts numbering in the millions worldwide. Clinical studies included targeted immunogenicity and safety substudies for these groups, often with cohorts of 100–500 participants per subgroup.

The Others segment, including high-risk adult and immunocompromised groups, is estimated at USD 41.02 million in 2025, contributing a 20.5% share, and expected to grow at a CAGR of 7.3%.

Top 5 Major Dominant Countries in the Others Application

• United States: Valued at USD 12.4 million with a 30.2% share and 7.3% CAGR, supported by vaccination awareness campaigns.
• Germany: Estimated at USD 9.0 million with a 21.9% share and 7.2% CAGR, due to adult RSV trial expansions.
• China: Holds USD 8.2 million with a 20.0% share and 7.4% CAGR, driven by increasing hospital-based immunization.
• France: At USD 6.4 million with a 15.6% share and 7.2% CAGR, supported by ongoing clinical development.
• Japan: Projected at USD 5.2 million with a 12.3% share and 7.1% CAGR, due to increased focus on adult vaccine adoption.

RSV Vaccine Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Regional performance in 2024 showed high early adoption in high-income markets with regulatory approvals and rollout plans: North America and Europe led initial uptake with multiple authorizations and program planning covering tens of millions of eligible adults, Asia-Pacific displayed rapid clinical trial activity and manufacturing expansion, and Middle East & Africa reflected nascent procurement with pilot access programs totaling hundreds of thousands of doses targeted in 2024–2025.

NORTH AMERICA

North America became an early adopter of RSV vaccines with 3 adult vaccines approved or recommended for adult use by 2024–2025, and CDC guidance recommending vaccination for all adults aged 75+ and high-risk adults 50–74. The U.S. saw major clinical investments: adult Phase III trials enrolled more than 35,000 participants in key programs, and maternal immunization studies tracked thousands of pregnancies with infant outcome follow-up for 90 and 180 day windows.

The North America RSV Vaccine Market is valued at USD 76.85 million in 2025, holding a 38.4% share, and is projected to expand at a CAGR of 7.3%, driven by advanced clinical trials and high vaccine coverage.

North America - Major Dominant Countries in the “RSV Vaccine Market”

• United States: At USD 53.6 million with a 69.7% share and 7.3% CAGR, leading the region through innovation and commercialization.
• Canada: Valued at USD 11.5 million with a 15.0% share and 7.2% CAGR, due to rising immunization investments.
• Mexico: Estimated at USD 6.7 million with an 8.7% share and 7.4% CAGR, supported by healthcare access improvements.
• Cuba: Holds USD 2.9 million with a 3.8% share and 7.3% CAGR, backed by expanding vaccine trials.
• Costa Rica: Projected at USD 2.2 million with a 2.8% share and 7.1% CAGR, due to regional health initiatives.

EUROPE

Europe played a leading role with 1 of the earliest regulatory approvals for adult RSV vaccines in June 2023, and expanded age indications followed in 2024 across multiple markets. European national immunization programs vary: some countries prioritized older adults 60+ while others targeted high-risk cohorts in the 50–59 bracket, creating heterogeneous demand profiles and procurement cycles. In 2024, European vaccine portfolios emphasized dairy dossier submissions and safety monitoring with 12–24 month post-authorization surveillance commitments.

The Europe RSV Vaccine Market is projected at USD 64.04 million in 2025, accounting for a 32.0% share, and growing at a CAGR of 7.2%, supported by cross-border collaborations in clinical research and vaccine development.

Europe - Major Dominant Countries in the “RSV Vaccine Market”

• Germany: Estimated at USD 17.9 million with a 27.9% share and 7.2% CAGR, led by vaccine technology advancements.
• France: Holds USD 14.6 million with a 22.8% share and 7.3% CAGR, supported by government immunization funding.
• United Kingdom: Valued at USD 13.7 million with a 21.4% share and 7.1% CAGR, driven by ongoing clinical partnerships.
• Italy: Projected at USD 10.2 million with a 15.9% share and 7.2% CAGR, due to emerging vaccine awareness programs.
• Spain: At USD 7.7 million with a 12.0% share and 7.2% CAGR, supported by healthcare modernization.

ASIA-PACIFIC

Asia-Pacific showed rapid clinical and manufacturing activity: 70% of regional clinical investment concentrated in China, Japan, and India, and the region accounted for a growing share of Phase II/III trial sites in 2023–2025. Asia-Pacific vaccine candidates included both global platform technologies and locally developed live-attenuated or intranasal candidates, with approximately 18% expansion in regional fill-finish capacity between 2023–2024.

The Asia RSV Vaccine Market stands at USD 45.83 million in 2025, contributing a 22.9% share, and is expected to grow at the highest CAGR of 7.5%, driven by population growth and expanding immunization networks.

Asia - Major Dominant Countries in the “RSV Vaccine Market”

• China: Valued at USD 17.4 million with a 38.0% share and 7.6% CAGR, supported by rapid biotech sector growth.
• Japan: Holds USD 11.9 million with a 25.9% share and 7.3% CAGR, backed by government-sponsored vaccine trials.
• India: Estimated at USD 8.7 million with a 19.0% share and 7.6% CAGR, due to expanding vaccine manufacturing facilities.
• South Korea: At USD 4.4 million with a 9.6% share and 7.4% CAGR, led by technology-driven clinical research.
• Australia: Projected at USD 3.4 million with a 7.5% share and 7.2% CAGR, owing to growing preventive health initiatives.

MIDDLE EAST & AFRICA

Middle East & Africa (MEA) represented an emerging access frontier with initial procurement and pilot programs representing hundreds of thousands of doses in 2024–2025, and regional interest focused on maternal immunization as an early pathway to protect infants. GCC countries accounted for a larger portion of early demand in MEA, with concentrated public health budgets enabling advance purchase agreements for tens to hundreds of thousands of doses in some states.

The Middle East and Africa RSV Vaccine Market is valued at USD 13.41 million in 2025, with a 6.7% share, and is expected to grow at a CAGR of 7.1%, driven by improving healthcare infrastructure and vaccination awareness.

Middle East and Africa - Major Dominant Countries in the “RSV Vaccine Market”

• Saudi Arabia: Valued at USD 4.3 million with a 32.1% share and 7.1% CAGR, due to health system modernization.
• UAE: Estimated at USD 3.2 million with a 23.9% share and 7.0% CAGR, driven by vaccination policy expansion.
• South Africa: Holds USD 2.7 million with a 20.1% share and 7.2% CAGR, supported by national immunization drives.
• Egypt: At USD 1.9 million with a 14.2% share and 7.0% CAGR, owing to healthcare accessibility growth.
• Israel: Projected at USD 1.4 million with a 9.7% share and 7.1% CAGR, due to collaborative RSV research programs.

List of Top RSV Vaccine Companies

• Pfizer
• GSK
• Moderna
• JNJ
• Bavarian Nordic
• Nuance Pharma
• Advaccine

GSK: one of the first adult RSV vaccine approvals in June 2023, with regulatory authorizations in 60+ countries and leading market positioning in older adult programs.

Pfizer: obtained adult and maternal indications with pivotal trial data showing infant protection efficacy near 82% in the initial 90 days and robust adult trial enrollment figures, supporting broad program adoption.

Investment Analysis and Opportunities

Investment analysis for the RSV Vaccine Market highlights capital allocation toward manufacturing scale, clinical evidence generation, and access strategies: 30+ clinical candidates signaled sustained R&D demand and 4+ Phase III programs created near-term commercial opportunities for manufacturing partners. Investors focus on fill-finish capacity expansions that increase regional output by 18–25%, and on mRNA platform manufacturing that can reduce development timelines by 30–50%. 

New Product Development

New product development between 2023–2025 included approvals, pivotal data readouts, and platform innovations: 3 adult RSV vaccines gained authorization by 2024, and mRNA platforms entered clinical authorization pathways with the first mRNA RSV approval in 2024, opening up scalable production models. Product formats in development included intramuscular, intranasal, and maternal injection regimens with multiple trials assessing single-dose and two-dose schedules; Phase III adult trials enrolled cohorts numbering in the tens of thousands while maternal trials followed thousands of pregnant participants with infant follow-up at 90 and 180 days.

Five Recent Developments

• June 2023 — A recombinant adjuvanted adult RSV vaccine received regulatory authorization in Europe and other markets, marking 1 of the first adult approvals in 2023 and enabling immediate national program considerations.
• May 2023–May 2024 — A pharmaceutical company secured maternal indication trial results showing infant protection efficacy of approximately 82% at 90 days and ~70% at 180 days, accelerating maternal program planning.
• May 2024 — The first mRNA RSV vaccine received an authorization for older adults, representing 1 mRNA authorization milestone and inaugurating mRNA platform entry into the RSV Vaccine Market.
• December 2024 — Pediatric RSV vaccine trials were placed on hold, impacting 26 pediatric INDs and 15 live-attenuated programs and delaying infant candidate timelines by 12–18 months.
• 2024–2025 — CDMOs and vaccine manufacturers announced capacity expansions and 20+ partnership agreements to increase fill-finish and regional manufacturing capacity by roughly 18–25% to meet adult and maternal demand projections.

Report Coverage of RSV Vaccine Market

This RSV Vaccine Market Research Report and RSV Vaccine Industry Report cover the global landscape across development stage, application, region, and supply chain. The report uses 2024 as the pivotal base year and documents historical activity from 2018–2023 plus pipeline projections into 2025–2027; it catalogs 30+ clinical candidates in development and 26 pediatric INDs filed in 2024, with 4+ Phase III adult programs producing pivotal efficacy data from trials enrolling >35,000 participants in at least one program. 

RSV Vaccine Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 214.74 Million in 2026
Market Size Value By	USD 404.86 Million by 2035
Growth Rate	CAGR of 7.3% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Clinical I Clinical II Clinical III Preclinical Being Developed By Application : Elderly Vaccine Infant Vaccine Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample